Clinical Trial Update: A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of AK105 (anti-PD-1) and Anlotinib for first-line hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib (anlotinib)

Snippet

Sponsor: Akeso | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED